|
Clinical and Molecular Hepatology (CMH) 현황 및 변경사항 보고 
Noticeable article in CMH Volume 30(1); Jan 2024
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Ying-Nan Tsai1, 2, Jia-Ling Wu3, Cheng-Hao Tseng1, 2, Tzu-Haw Chen4, Yi-Ling Wu4, Chieh-Chang Chen5, 6, Yu-Jen Fang6, 7, Tzeng-Huey Yang8, Mindie H. Nguyen9, 10, Jaw-Town Lin4, Yao-Chun Hsu2, 4
1Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan
2School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
3Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan
4Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
5Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
6Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
7Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan
8Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Yilan, Taiwan
9Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA
10Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA, USA
• Posttreatment HBcrAg levels more accurately predict clinical relapse following discontinuation of entecavir or tenofovir than end-of-treatment HBcrAg and dynamic HBsAg levels do
• An HBcrAg level below 1,000 U/mL during the posttreatment follow-up indicates a low risk of subsequent clinical relapse
• Changes in HBcrAg levels after treatment in CHB patients are typically minor and the patterns of changes are not independently linked to clinical relapse risk.
DOI:https://doi.org/10.3350/cmh.2023.0194
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar1, Jun Gong1, Arsen Osipov1, Steven A. Miles1, Kambiz Kosari1, 2, Nicholas N. Nissen1, 2, Andrew E. Hendifar1, Ekaterina K. Koltsova1, 3, Ju Dong Yang1, 2, 4
1Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
3Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
4Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
• There have been significant advances in the systemic treatment options for HCC over the past decades, with several approvals of both immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with preserved liver function.
• Several ongoing and promising trials are now evaluating combinational strategies with novel systemic agents and combinations of systemic therapy with locoregional therapy. In view of these trials, further advances in the treatment of HCC are foreseen in the near future.
DOI: https://doi.org/10.3350/cmh.2023.0125
|
INTRO
로그인
회원가입안내
목록
이메일 무단 수집 거부